Mezlocillin (subcutaneous injection; 1.7-5.7 mg/kg; twice daily; 7 d) treatment in vivo suppresses the IgM and IgG responses and the delayed-type hypersensitivity reaction, observes the loss of hair, and inhibits lymphocyte proliferation of animals treated with all doses[1].
| Animal Model: | Male Balb/c mice[1] |
| Dosage: | 1.7, 4.3, and 5.7 mg/kg |
| Administration: | Subcutaneous injection; 1.7, 4.3, and 5.7 mg/kg; twice daily; 7 days |
| Result: | Suppressed the IgM and IgG responses and the delayed-type hypersensitivity reaction treated with all doses.
Observed a loss of hair in the majority of animals treated with all doses.
Inhibited lymphocyte proliferation of spleen-cell cultures from animals. |
![4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, monosodium salt, [2S-[2alpha,5alpha,6beta(S*)]]- Structure](/CAS/GIF/42057-22-7.gif)
